quinaprilat has been researched along with rxp 407 in 2 studies
| Studies (quinaprilat) | Trials (quinaprilat) | Recent Studies (post-2010) (quinaprilat) | Studies (rxp 407) | Trials (rxp 407) | Recent Studies (post-2010) (rxp 407) |
|---|---|---|---|---|---|
| 92 | 23 | 4 | 15 | 0 | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batenburg, WW; Danser, AH; de Bruijn, RJ; de Vries, R; Dive, V; Georgiadis, D; Tom, B; van Esch, JH; van Gool, JM; Yiotakis, A | 1 |
| de Bruin, RJ; Deinum, J; Dive, V; Hectors, M; Jan Danser, AH; Montgomery, HE; Payne, JR; van Esch, JH; van Gool, JM | 1 |
2 other study(ies) available for quinaprilat and rxp 407
| Article | Year |
|---|---|
Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
Topics: Adolescent; Adult; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Captopril; Coronary Vessels; Dose-Response Relationship, Drug; Female; Femoral Artery; Humans; Male; Microcirculation; Middle Aged; Oligopeptides; Organ Specificity; Peptidyl-Dipeptidase A; Phosphinic Acids; Protein Structure, Tertiary; Solubility; Structure-Activity Relationship; Sus scrofa; Tetrahydroisoquinolines; Vasoconstriction | 2005 |
Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
Topics: Adult; Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Coronary Vessels; Enzyme Activation; Female; Genotype; Humans; In Vitro Techniques; Male; Middle Aged; Oligopeptides; Peptidyl-Dipeptidase A; Phosphinic Acids; Point Mutation; Protein Structure, Tertiary; Sus scrofa; Tetrahydroisoquinolines; Vasoconstrictor Agents; Vasodilator Agents | 2008 |